• Xueyan Lv and Xingyu Kang.
• The First Clinical Medical College of Heilongjiang University of Chinese Medicine, Haerbin, Heilongjiang Province, China.
• Medicine (Baltimore). 2024 Jun 7; 103 (23): e38504e38504.

ObjectiveTo systematically evaluate the efficacy of Er Chen Tang in the adjuvant treatment of obesity.MethodsA computerized search of databases such as CNKI, Wanfang, Wipro, EMBase, Web of Science, PubMed, and Cochrane Library was performed to collect randomized controlled trials on the application of Er Cheng Tang for the treatment of obesity and to track the references included in the literature, with a timeframe from the establishment of the library to October 2023 for the searches. After selection of trials, extraction of information and assessment of methodological quality were done independently by 2 evaluators, meta-analysis was performed using RevMan 5.3 software and the quality of evidence was evaluated using the Cochrane system.ResultsSix studies were included, with a total of 438 study participants. They were randomized into trial and control groups. The total cholesterol, triglyceride, low-density lipoprotein cholesterol, body mass index, and visceral fat area values before treatment were compared between the 2 groups, and the differences were not statistically significant (all P > .05). After treatment, the indicators of the experimental group were significantly better than those of the control group, and the differences were all statistically significant (P < .05).ConclusionThe adjuvant treatment of obesity with Er Chen Tang can improve the symptoms faster and is favorable to the reduction of various risk indicators. However, due to the lack of high-quality literature, the theoretical support of large-sample double-blind randomized trials is still needed in the future.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

10 keywords...

hide…